With less than 2% Illumina stock stake, activist’s claims get company pushback Illumina (NASDAQ:ILMN) is hitting back at activist investor Carl Icahn as the genome sequencing biotech firm disputed his inflamatory claims and rejected his proposed board nominations. Icahn, who owns a 1.4% stake in Illumina, began his latest proxy battle on March 13, criticizing […]